Search

Displaying results 8611 - 8620 of 10000 in total
  1. Drug

    Batefenterol

    go.drugbank.com/drugs/DB12526
    Investigational

    Batefenterol has been used in trials studying the treatment of Pulmonary Disease, Chronic Obstructive.

  2. Drug

    Ulotaront

    go.drugbank.com/drugs/DB15665
    Investigational

    [L12891] An initial clinical study has shown this drug may be effective against both positive and negative symptoms of schizophrenia. … Unlike other drugs used for this condition, SEP-363856 does not bind to the dopamine D2 receptors, but exerts actions on the trace amine–associated receptor 1 (TAAR1) and 5-hydroxytryptamine type 1A (5

  3. Drug

    Lemuteporfin

    go.drugbank.com/drugs/DB04980
    Investigational

    Lemuteporfin, under development by QLT Incorporated, is a benzoporphyrin-derived chlorin-like photosensitizer. It is intended for the treatment of beign prostatic hyperplasia.

  4. Drug

    Flovagatran

    go.drugbank.com/drugs/DB05714
    Experimental

  5. Drug

    LCP-AtorFen

    go.drugbank.com/drugs/DB05769
    Investigational

    LCP-AtorFen is a fixed-dose combination therapy for the treatment of high cholesterol levels combining atorvastatin (the active ingredient of Lipitor®) and the lowest dose of fenofibrate without food effect. LCP-AtorFen is designed to be...

  6. Drug

    CVT-6883

    go.drugbank.com/drugs/DB05936
    Experimental

    CVT-6883 is a selective, potent and orally available A2B-adenosine receptor antagonist which CV Therapeutics is investigating for the potential treatment of asthma and other conditions related to inflammation and fibrosis.

  7. Drug

    Thrombopoietin

    go.drugbank.com/drugs/DB06534
    Investigational

  8. Drug

    Estradiol sulfamate

    go.drugbank.com/drugs/DB06597
    Investigational

  9. Drug

    Ilepatril

    go.drugbank.com/drugs/DB06604
    Investigational

  10. Drug

    Otamixaban

    go.drugbank.com/drugs/DB06635
    Investigational

    Otamixaban is a novel direct Factor Xa (FXa) inhibitor. It is currently being developed by the French pharmaceutical company Sanofi-Aventis as a treatment for acute coronary syndrome.